[
    {
        "content": "* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S",
        "date": "11082017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen Inc reports Q3 loss per share $0.50 "
    },
    {
        "content": "* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)",
        "date": "10182017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease "
    },
    {
        "content": "* \u200dAnnounced results from co's phase 2b randomized  double-blind  placebo-controlled study in patients with idiopathic pulmonary fibrosis\u200b",
        "date": "09132017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen's \u200dPamrevlumab was well tolerated with no safety risks "
    },
    {
        "content": "* Fibrogen  Inc. announces pricing of follow-on offering of common stock",
        "date": "08162017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen announces pricing of follow-on offering of common stock "
    },
    {
        "content": "* Fibrogen Inc announces proposed follow-on offering of common stock",
        "date": "08142017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-FibroGen announces proposed follow-on offering of common stock "
    },
    {
        "content": "* Fibrogen Inc - \u200dnet loss per basic and diluted share for quarter ended June 30  2017 was $0.48 - SEC filing\u200b",
        "date": "08072017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen \u200dnet loss per diluted share for quarter ended June 30 was $0.48 "
    },
    {
        "content": "* Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S",
        "date": "08072017",
        "name": "FibroGen Inc",
        "news_type": "normal",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen Inc reports Q2 loss per share $0.48 "
    },
    {
        "content": "* Q1 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S",
        "date": "05092017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen reports Q1 loss per share $0.52 "
    },
    {
        "content": "* Fibrogen  Inc. announces pricing of follow-on offering of common stock",
        "date": "04062017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen reports pricing of follow-on offering of common stock "
    },
    {
        "content": "* Fibrogen announces china fda approval of cta to conduct pivotal phase 2/3 clinical trial of roxadustat in anemia associated with lower risk mds",
        "date": "03312017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen wins China clearance to conduct key study testing roxadustat "
    },
    {
        "content": "* Fibrogen Inc files for potential mixed shelf offering; size not disclosed  Source text:(http://bit.ly/2mGofE4) Further company coverage:",
        "date": "03012017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen Inc files for potential mixed shelf offering "
    },
    {
        "content": "* Sees to report pamrevlumab topline phase 2 ipf data  placebo-controlled and combination treatment sub-study results  in q3",
        "date": "03012017",
        "name": "FibroGen Inc",
        "news_type": "normal",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen reports fiscal 2016 financial results "
    },
    {
        "content": "* FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China",
        "date": "01302017",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China "
    },
    {
        "content": "* Fibrogen reports financial results for the third quarter of 2016 and provides corporate update",
        "date": "11082016",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen reports Q3 loss per share $0.38 "
    },
    {
        "content": "* Says topline data from trials on roxadustat expected by early 2017",
        "date": "10312016",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-FibroGen completes enrollment in Roxadustat Phase 3 studies in China "
    },
    {
        "content": "* Fibrogen reports financial results for the second quarter of 2016",
        "date": "08082016",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen reports Q2 EPS of $0.39 "
    },
    {
        "content": "* Fibrogen announces receipt of $62 million license payment  from Astrazeneca",
        "date": "07082016",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen announces receipt of $62 million license payment from Astrazeneca "
    },
    {
        "content": "* Fibrogen reports financial results for the first quarter of 2016",
        "date": "05092016",
        "name": "FibroGen Inc",
        "news_type": "topStory",
        "symbol": "FGEN",
        "title": "BRIEF-Fibrogen Q1 loss per share $0.45 "
    }
]